Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 7/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | NQO1 | P15559 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21171731 | 0.82 | HSD17B3 (0.43) | HSD17B3CA12CA1CA9NQO1 | |
| SCHEMBL21533753 | 0.82 | CA12 (0.44) | HSD17B3CA12CA1CA9NQO1 | |
| SCHEMBL21533752 | 0.81 | HSD17B3 (0.44) | HSD17B3CA12CA1CA9NQO1 | |
| SCHEMBL21171753 | 0.79 | CA12 (0.41) | CA12CA1CA9NQO1CYP19A1 | |
| SCHEMBL21172146 | 0.79 | NPC1 (0.44) | HSD17B3CA12CA1CA9NQO1 | |
| SCHEMBL21533671 | 0.78 | KDM4E (0.44) | HSD17B3CA12CA1CA9NQO1 | |
| SCHEMBL24487015 | 0.78 | CA12 (0.42) | HSD17B3CA12CA1CA9NQO1 | |
| SCHEMBL24487069 | 0.77 | KCNA3 (0.40) | CA12CA1CA9NQO1CYP19A1 | |
| SCHEMBL24487061 | 0.77 | KMT2A (0.42) | HSD17B3CA12CA1CA9CYP19A1 | |
| SCHEMBL24487010 | 0.77 | HSD17B3 (0.45) | HSD17B3CA12CA1CA9NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220412963-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11353461-B2 | Methods of enhancing MS detection of tagged glycans | WATERS TECHNOLOGIES CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | WATERS TECHNOLOGIES CORPORATION (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190219587-A1 | METHODS OF ENHANCING MS DETECTION OF TAGGED GLYCANS | WATERS TECHNOLOGIES CORPORATION | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | FUT5, FUT6, OGT | HSD17B3 4002/4885CA12 1131/4885CA1 3311/4885 |
| US-20220412963-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | FUT5, FUT6, OGT | HSD17B3 4002/4885CA12 1131/4885CA1 3311/4885 |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | FUT5, FUT6, OGT | HSD17B3 4002/4885CA12 1131/4885CA1 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.